• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

by Elena Iemma | May 25, 2022 | News

PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration...
Recorded: EpiVax EPV-CoV-19 Vaccine Webinar

Recorded: EpiVax EPV-CoV-19 Vaccine Webinar

by Annie De Groot | Sep 21, 2020 | Events, Webinars

Thank you for your continued interest in the status of our EpiVax’s EPV-CoV-19 Vaccine Program. This event has passed! But do not fear, there is a recording of the session available for access. Kindly fill out the information form linked below and an email...
Providence biotech firm is working on a coronavirus vaccine – Boston Globe interview

Providence biotech firm is working on a coronavirus vaccine – Boston Globe interview

by Adam | Mar 30, 2020 | News

With 22 years of experience, EpiVax is in the ‘perfect position’ to figure out how to immunize people, founder says By Edward Fitzpatrick Globe Staff,Updated March 30, 2020, 6:00 a.m. Read the full text here. The Boston Globe’s weekly Ocean State Innovators column...

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.